Bind And Amgen To Inhibit Kinases | Chemical & Engineering News
Volume 91 Issue 2 | p. 21 | Concentrates
Issue Date: January 14, 2013

Bind And Amgen To Inhibit Kinases

Department: Business
Keywords: cancer, pharmaceuticals, kinase inhibitors, nanomedicine

Bind Biosciences will work with Amgen to develop kinase inhibitor nanomedicines to treat a range of solid tumors. Cambridge, Mass.-based Bind says it could receive up-front and development milestone payments totaling $46.5 million and up to $134 million more for regulatory and sales milestones. Bind is developing targeted and programmable therapeutics it calls Accurins. The partners are looking to develop a new Accurin around a proprietary kinase inhibitor from Amgen.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment